SpringWorks Therapeutics expects EMA review for nirogacestat in Q2 2025 for desmoid tumor treatment.

From GlobeNewswire: 2025-04-27 10:35:00

SpringWorks Therapeutics, Inc. expects the EMA to review the marketing application for nirogacestat in Q2 2025, focusing on treatment for adults with desmoid tumors. The company is dedicated to rare disease and cancer treatments, with OGSIVEO® and GOMEKLI™ already approved by the FDA. SpringWorks also has a pipeline of targeted therapy products for solid tumors and hematological cancers. Forward-looking statements caution about potential risks and uncertainties, and readers are advised to review the company’s Annual Report for more information. Contacts for media and investors are available for further inquiries.



Read more at GlobeNewswire: SpringWorks Therapeutics Announces Expected CHMP Opinion in